Polymorph Control in MSMPR Crystallizers. A Case Study with Paracetamol

Process Performance and Operational Challenges in Continuous Crystallization: A Study of the Polymorphs of L-Glutamic Acid

The crystallization of the two polymorphs of l-glutamic acid (LGA) is carried out in a continuous crystallization process, and its performance according to different criteria is evaluated. The study aims at identifying suitable operating conditions for producing either αLGA or βLGA with a high polymorphic purity. To this end, we investigate the process both from a theoretical perspective and through experiments using either a single stirred-tank crystallizer or a cascade of two stirred-tank crystallizers in series. In terms of theory, we extend the MSMPR-based steady-state stability analysis of Farmer et al. (Farmer, T. C. et al. AIChE J.2016, 62, 3505-3514) by accounting for the possibility of a nonrepresentative withdrawal of the solid phase from the crystallizer. Additionally, the process is simulated using population balance equations, thereby investigating the effect of operating conditions on polymorphic purity, yield, and productivity. Guided by the model-based conclusions, we identified suitable operating conditions and experimentally tested them. The experimental campaign has demonstrated that βLGA could be successfully and continuously produced in both process configurations according to the theory with performance as expected, whereas that was not possible for αLGA. The difference between the two stems from different operational challenges, whose consequence is that steady-state operation is attained in the case of βLGA but not in that of αLGA. In the former case, the needle-like βLGA crystals, which exhibit no agglomeration, tend to be only slightly oversampled; in the latter case, the prismatic αLGA crystals undergo major agglomeration and hence are very difficult to suspend and effectively withdraw from the crystallizer.

Secondary Nucleation by Interparticle Energies. III. Nucleation Rate Model

A nucleation rate model for describing the kinetics of secondary nucleation caused by interparticle energies (SNIPEs) is derived theoretically, verified numerically, and validated experimentally. The theoretical derivation reveals that the SNIPE mechanism can be viewed as enhanced primary nucleation, i.e., primary nucleation with a lower thermodynamic energy barrier (for nucleation) and a smaller critical nucleus size, both caused by the interparticle interactions and the associated energy between the surface of a seed crystal and a molecular cluster in solution, as shown in part I of this series. In the case of a sufficiently agitated suspension, the model depends on four parameters: two reflecting primary nucleation kinetics and the other two accounting for the intensity and effective spatial range of the interparticle interactions. As a numerical verification of the model, we show that the nucleation kinetics described by the SNIPE rate model is in quantitative agreement with those given by the kinetic rate equation model developed in part II of this series. A sensitivity analysis of the SNIPE rate model is conducted to present the effect of key model parameters on the nucleation kinetics. Moreover, the SNIPE rate model is validated by fitting the model to the time-resolved data of secondary nucleation experiments as well as to two other, well-known secondary nucleation rate models. Importantly, all of the estimated parameter values for the SNIPE model were consistent with the theoretical estimates, while some of the estimated parameter values for one of the well-known secondary nucleation models deviated from the corresponding theoretical values significantly.

Crystallization of Form II Paracetamol with the Assistance of Carboxylic Acids toward Batch and Continuous Processes

Form II paracetamol has captured the interest of researchers due to its improved compressibility. However, its low stability has made it difficult to be produced on a large scale with good reproducibility. In the present study, the selective polymorphic formation of paracetamol was carried out by cooling crystallization with four types of additives: adipic acid, fumaric acid, oxalic acid, and succinic acid. It was found that: (1) the more additives that were added, the higher the probability of forming Form II paracetamol; (2) Form II paracetamol could be induced by seeding the paracetamol aqueous solution with Form II paracetamol and fumaric acid crystals, and not the other three carboxylic acids; (3) a new solution complex of paracetamol-oxalic acid, evidenced by the solubility diagram, was responsible for the selective nucleation of Form II paracetamol in the oxalic acid aqueous solution; and (4) the range of the degree of supersaturation for nucleating Form II paracetamol was extended with the assistance of oxalic acid or fumaric acid. In large-scale crystallization, Form II paracetamol was produced by the continuous crystallization of 44 mg of paracetamol/mL in 50 wt% of fumaric acid aqueous solution with a flow rate of 150 mL/min.

Impurity incorporation in solution crystallization: diagnosis, prevention, and control

This work highlights recent advances in the diagnosis, prevention, and control of impurity incorporation during solution crystallization.

Selective formation of form II paracetamol through the assistance of paracetamol co-crystals as templates in a solution

The arrangement of paracetamol templated by the structure of 1 : 1 co-crystal of paracetamol–maleic acid in solution phase facilitating the nucleation of metastable form II paracetamol.

Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization

Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal size and habit further contribute to this variability. An important focus in pharmaceutical research has been on controlling the drug form to improve the solubility and thus bioavailability of APIs. In this regard, heterogeneous crystallization on surfaces and crystallization under confinement have become prominent forms of controlling polymorphism and drug crystal size and habits; however there has not been a thorough review into the emerging field of combining these approaches to control crystallization. This tutorial-style review addresses the major advances that have been made in controlling API forms using combined crystallization methods. By designing templates that not only control the surface functionality but also enable confinement of particles within a porous structure, these combined systems have the potential to provide better control over drug polymorph formation and crystal size and habit. This review further provides a perspective on the future of using a combined crystallization approach and suggests that combining surface templating with confinement provides the advantage of both techniques to rationally design systems for API nucleation.